What is Alexion?
Alexion is a global biopharmaceutical company established in 1992 and headquartered in Boston, Massachusetts. Its core mission revolves around the discovery, development, and commercialization of medicines designed to treat severe and life-threatening rare disorders. The company's focus on unmet medical needs in niche patient populations positions it as a key player in the specialized biopharmaceutical sector, driving innovation for conditions that often lack effective therapeutic options.
How much funding has Alexion raised?
Alexion has raised a total of $18M across 1 funding round:
Stock Offering
$18M
Stock Issuance/Offering (1996): $18M, investors not publicly disclosed
What's next for Alexion?
The recent major strategic investment in Alexion signals a phase of accelerated growth and potential expansion of its therapeutic pipeline or market reach. This capital infusion is likely to fuel further research and development into novel treatments for rare diseases, potentially leading to new drug approvals and enhanced patient access. The company's trajectory suggests a continued commitment to addressing complex genetic and acquired rare conditions, leveraging its expertise to build a robust portfolio.
See full Alexion company page
